Literature DB >> 23750363

Mycobacterium fortuitum endocarditis associated with cardiac surgery, Serbia.

Dragana Vuković, Vojislav Parezanović, Branislava Savić, Ivana Dakić, Suzana Laban-Nestorović, Slobodan Ilić, Ivana Ćirković, Srdjan Stepanović.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23750363      PMCID: PMC3647651          DOI: 10.3201/eid1903.120763

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Mycobacterium fortuitum is a member of the group of rapidly growing nontuberculous mycobacteria. It is a well-known causative agent of skin and soft tissue infections, postsurgical wound infections, and other health care–associated infections (). Only sporadic cases of endocarditis caused by this bacterium have been reported (–). We describe a cardiac surgery–related outbreak of endocarditis caused by M. fortuitum in 3 children. Over a 3-week period during 2009, eight children consecutively underwent surgery for correction of ventricular septal defect (VSD) by insertion of a bovine pericardial patch at the University Children’s Hospital in Belgrade, Serbia. None of them had previous cardiac surgery. The same patch, SJM Pericardial Patch with EnCap Technology (St. Jude Medical, St. Paul, MN, USA), was used as a source for smaller, tailored patches for all patients. Sterile scissors and forceps were used to tailor a piece of the patch needed for a corresponding VSD closure. During repeated performances of this procedure and between surgeries, the patch had been continuously stored in 2% propylene oxide (PO) provided by the manufacturer. Each tailored piece of the patch had been immersed into freshly prepared sterile saline for 6 min before defect patching. The postoperative course had been uneventful for all patients, and they were discharged 7 days after the procedure. However, 3 patients were readmitted to the hospital because of prolonged fever and increasing fatigue. Patients 1, 2, and 3 (Table) had been the fourth, sixth, and eighth patients undergoing VSD repair, respectively. Diagnosis of infective endocarditis in these patients was established by transthoracic echocardiography findings and blood cultures positive for acid-fast bacteria (Table). Acid-fast bacteria also were recovered from the patch and vegetation taken during reoperation in patient 3 (Table). The isolates were identified as M. fortuitum by the GenoType Mycobacterium CM assay (Hain Lifescience, Nehren, Germany) (). Empiric treatment with vancomycin and ceftriaxone was switched to amikacin, ciprofloxacin, and imipenem. After 6 weeks of treatment, the patients were discharged, and all were asymptomatic 12 months later.
Table

Characteristics of patients in an outbreak of Mycobacterium fortuitum endocarditis, Serbia*

CharacteristicPatient 1Patient 2Patient 3
Age, y/sex12.0/F2.0/F0.5/M
ComorbidityNoDown syndromeNo
Time between surgery and readmission, d869776
Position of vegetationSeptal cusp of tricuspid valveSeptal cusp of tricuspid valve and VSD patchSeptal cusp of tricuspid valve and VSD patch
Hemodynamic consequenceModerate tricuspid valve regurgitationModerate tricuspid valve regurgitationVSD patch dehiscence
No. blood cultures collected, aerobic/anaerobic3/310/46/3
No. blood cultures positive for acid-fast bacteria, aerobic/anaerobic2/05/02/0
Time of collection of first positive/last positive blood culture, d after readmission8/111/214/16
OutcomeResolved after antimicrobial drug treatmentResolved after antimicrobial drug treatmentResolved after antimicrobial drug treatment and reoperation

*VSD, ventricular septal defect.

*VSD, ventricular septal defect. The cultural characteristics and susceptibility patterns of all the isolates obtained were indistinguishable. To explore their possible clonal relatedness, we genotyped 3 M. fortuitum strains isolated from blood cultures (1 isolate per patient) and 2 M. fortuitum isolates recovered from samples taken during reoperation in 1 of the patients. The enterobacterial repetitive intergenic consensus PCR was used (), and all isolates produced identical patterns. Nosocomially acquired M. fortuitum endocarditis has been reported but only sporadically in adults, and these cases usually were fatal (,,). In contrast, we describe 3 related cases of M. fortuitum endocarditis in children who recovered. The relatedness of the cases is strongly supported by the following. First, epidemiologic links are obvious because the 3 patients underwent surgery in the same operating room, and the same patch was used in all of them. Second, M. fortuitum strains isolated from the 3 patients were phenotypically and genotypically identical. Repeated use of the same patch in multiple surgeries strongly suggests the contaminated patch was the source of M. fortuitum infection in the 3 patients. This possibility could not be corroborated by bacteriologic examination of the patch because the remaining unusable fragments had been discarded after the surgeries (i.e., ≈3 months before the outbreak became evident). Although contamination of the patch during manufacture is possible (), it seems more reasonable to assume that the contamination occurred intraoperatively. The common factor in nosocomially acquired M. fortuitum infections is presumed to be exposure to a liquid contaminated with this organism (,). The patch was not exposed to solutions other than the PO in which it had been stored and the sterile saline used during the rinsing procedure. Because only a piece of the patch tailored for a particular patient was exposed to a saline freshly prepared for each surgery, contamination of the PO by M. fortuitum presumably led to contamination of the patch. Liquid PO is used as a chemical sterilant for bioprostheses intended for single use. However, multiple use of the same patch implied repeated exposure of the PO solution to the environment and prolonged storage at 4°C between surgeries. Because PO effectiveness is markedly reduced at temperatures <16°C (), the specific circumstances could have compromised the sterilizing capacity of the PO solution and enabled contamination by ubiquitous M. fortuitum. We are well aware that the patch was intended for single use only and that application of the same patch in multiple patients is not a practice in industrialized countries. However, it is a practice in some resource-limited countries. The outbreak of M. fortuitum endocarditis we describe is a clear warning that such practice is associated with high risk and thus should be discontinued.
  10 in total

Review 1.  Native valve endocarditis due to Mycobacterium fortuitum biovar fortuitum: case report and review.

Authors:  D W Spell; J G Szurgot; R W Greer; J W Brown
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

Review 2.  Pacemaker infection due to Mycobacterium fortuitum.

Authors:  Sunita Sharma; Imad M Tleyjeh; Raul E Espinosa; Brian A Costello; Larry M Baddour
Journal:  Scand J Infect Dis       Date:  2005

3.  Evaluation of the GenoType Mycobacterium Assay for identification of mycobacterial species from cultures.

Authors:  Elvira Richter; Sabine Rüsch-Gerdes; Doris Hillemann
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

Review 4.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

Review 5.  Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria.

Authors:  R J Wallace; B A Brown; D E Griffith
Journal:  Annu Rev Microbiol       Date:  1998       Impact factor: 15.500

Review 6.  Mycobacterium fortuitum complex endocarditis-case report and literature review.

Authors:  J Olalla; M Pombo; J M Aguado; E Rodríguez; E Palenque; J R Costa; E Riopérez
Journal:  Clin Microbiol Infect       Date:  2002-02       Impact factor: 8.067

7.  Mycobacterium chelonae valve endocarditis resulting from contaminated biological prostheses.

Authors:  T M V Strabelli; Rinaldo Focaccia Siciliano; Jussara Bianchi Castelli; L M M F Demarchi; Sylvia Cardoso Leão; Cristina Viana-Niero; Kozue Miyashiro; Roney Orismar Sampaio; Max Grinberg; David Everson Uip
Journal:  J Infect       Date:  2010-03-20       Impact factor: 6.072

8.  Application of four molecular typing methods for analysis of Mycobacterium fortuitum group strains causing post-mammaplasty infections.

Authors:  J L M Sampaio; E Chimara; L Ferrazoli; M A da Silva Telles; V M F Del Guercio; Z V N Jericó; K Miyashiro; C M C B Fortaleza; M C Padoveze; S C Leão
Journal:  Clin Microbiol Infect       Date:  2006-02       Impact factor: 8.067

Review 9.  Conservative treatment of prosthetic valve endocarditis due to Mycobacterium fortuitum.

Authors:  M Kunin; F Salamon; M Weinberger; I Genkin; A Sagie; R Tur-Kaspa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-07-10       Impact factor: 3.267

10.  The sterilizing capacity of propylene oxide and chlorhexidine diacetate solutions upon pre-injection swabs saturated with propan-2-ol.

Authors:  R C Wright
Journal:  J Hyg (Lond)       Date:  1983-10
  10 in total
  4 in total

Review 1.  Human pathogenic bacteria, fungi, and viruses in Drosophila: disease modeling, lessons, and shortcomings.

Authors:  Stavria Panayidou; Eleni Ioannidou; Yiorgos Apidianakis
Journal:  Virulence       Date:  2014-01-07       Impact factor: 5.882

2.  Native Pulmonic Valve Endocarditis due to Mycobacterium fortuitum: A Case Report and Literature Review.

Authors:  Aaron M Mulhall; Renee S Hebbeler-Clark
Journal:  Case Rep Infect Dis       Date:  2015-06-08

Review 3.  Mycobacterial endocarditis: a comprehensive review.

Authors:  Shi-Min Yuan
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jan-Mar

4.  Native valve endocarditis and pacemaker infection with Mycobacterium fortuitum.

Authors:  Moamen Al Zoubi; Joyce Cheng; Venkate S Dontaraju; Colin E Evans; Addie B Spier
Journal:  IDCases       Date:  2021-06-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.